公开(公告)号：US20230149381A1

公开(公告)日：2023-05-18

申请号：US17918829

申请日：2021-04-15

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Kyoko NISHIBATA ,  Sayo FUKUSHIMA ,  Satoshi KAWANO ,  Saori MIYANO

IPC: A61K31/4545 ,  A61K31/519 ,  A61K31/565 ,  A61P35/04

CPC classification number: A61K31/4545 ,  A61K31/519 ,  A61K31/565 ,  A61P35/04

Abstract: Provided is a therapeutic agent for treating breast cancer that has developed resistance to administration of CDK4/6 inhibitors and estrogen antagonists, the agent containing 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethox y)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

公开(公告)号：US20230330081A1

公开(公告)日：2023-10-19

申请号：US18030207

申请日：2021-10-26

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Taisuke HOSHI ,  Yu KATO ,  Yoichi OZAWA ,  Satoshi KAWANO ,  Kotaro KODAMA ,  Saori MIYANO

IPC: A61K31/4545 ,  A61P35/00

CPC classification number: A61K31/4545 ,  A61P35/00 ,  A61K2039/505

Abstract: Provided is a pharmaceutical composition for treating a tumor, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxyl-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt, which is to be administered in combination with a PD-1 antagonist.

公开(公告)号：US20190111043A1

公开(公告)日：2019-04-18

申请号：US16225772

申请日：2018-12-19

Applicant: NATIONAL CANCER CENTER ,  Eisai R&D Management Co., Ltd.

Inventor： Tatsuhiro SHIBATA ,  Yasuhito ARAI ,  Kenichi NOMOTO ,  Tomio NAKAMURA ,  Akihiko TSURUOKA ,  Saori MIYANO

IPC: A61K31/4545

Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

公开(公告)号：US20180015079A1

公开(公告)日：2018-01-18

申请号：US15547139

申请日：2016-03-23

Applicant: NATIONAL CANCER CENTER ,  Eisai R&D Management Co., Ltd.

Inventor： Tatsuhiro SHIBATA ,  Yasuhito ARAI ,  Kenichi NOMOTO ,  Tomio NAKAMURA ,  Akihiko TSURUOKA ,  Saori MIYANO

IPC: A61K31/4545

CPC classification number: A61K31/4545

Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.